ASKC202

Phase 1Small molecule

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

ASKC202 is one of 7 small molecule programs targeting Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TumorRecruiting

TumorPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Tumor

#DrugCompanyPhaseTrials

Giapreza

LLa Jolla Pharmaceutical Company

Phase 2

1 2

MRI Contrast-Enhancing Agents

Sanofi

Phase 1

1 3

HP518 - Dose Expansion

HHinova Pharmaceuticals Aus Pty Ltd

Phase 2

1 4

ASK120067

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 1

1 5

ASKC202

JJiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 1

1 6

STR-P004

SStarna Therapeutics

Preclinical

1 7

OBX-115

OObsidian Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Tumor

NCT05306132

Q4 2032

Phase 3Not yet recruiting

EGFR Activating Mutation

NCT07897188

Clinical

Trials by Indication[1]

Tumor1 trial

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

Recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 1·NCT05306132·150 enrolled

EGFR Activating Mutation1 trial

A Randomized, Controlled, Double-Blind, Multicenter, Phase 3 Clinical Study of ASKC202 Plus Limertinib Versus Osimertinib for First-Line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

Not yet recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 3·NCT07897188·425 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ASKC202. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASKC202 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASKC202. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Aosaikang Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJiangsu Aosaikang Pharmaceutical Co., Ltd.

ASKC202

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2032

Trials by Indication[1]

Tumor1 trial

EGFR Activating Mutation1 trial

References

Drug Info

Quick Facts

Related News